Gufic Biosciences profit and loss

Latest FY26

Revenue: ₹944cr+15.2% on FY25
EBITDA: ₹151cr+12.4% on FY25
Net profit: ₹64.2cr−7.8% on FY25
EPS: ₹6.40−7.9% on FY25

₹ crore except per share

Tap a line for its trend	Last 12Mto Jun 2026	FY26Mar 2026	FY25Mar 2025	FY24Mar 2024	FY22 and earlierAlpha Plus

Expenses
	981	944	820	807	FY22 and earlierEvery year the company has filed comes with Alpha Plus.
	2.2	2.7	3.6	2.2
	983	947	823	809
	443	425	344	341
	64.5	64.7	55.4	58.1
	−72.0	−68.9	−24.9	−9.5
	157	152	127	110
	36.7	36.6	23.1	15.4
	30.8	30.8	21.1	17.0
	224	220	183	161
	884	860	729	693
	165	151	135	146
	134	121	114	129
Profit
	99.3	86.5	94.1	116
	99.3	86.5	94.1	116
	17.6	13.7	18.7	26.4
	8.3	8.6	5.8	3.2
	25.9	22.3	24.5	29.5
	73.5	64.2	69.6	86.1
	73.5	64.2	69.6	86.1
	0.6	0.5	−0.1	−0.4
	74.0	64.7	69.5	85.7
	—	64.2	69.6	—
	—	−0.0	−0.0	—
Per share
	₹7.32	₹6.40	₹6.95	₹8.74
	₹7.32	₹6.40	₹6.95	₹8.74
Other comprehensive income — detail
	—	0.5	−0.1	—
	—	0.7	−0.2	−0.5
	—	0.2	−0.0	—
	—	—	—	−0.1
	—	64.2	69.6	—
	—	−0.0	−0.0	—
Per share — as-filed variants
	₹7.32	₹6.40	₹6.95	₹8.74
	₹7.32	₹6.40	₹6.95	₹8.74
Derived — gross profit (revenue − materials − purchases − Δ inventories)
	546	523	445	417
	55.6%	55.4%	54.3%	51.7%
Adjusted (ex-exceptional items) — derived
	99.3	86.5	94.1	116
	73.5	64.2	69.6	86.1
	₹7.32	₹6.40	₹6.95	₹8.74

Open the chart

From the company's filings with NSE and BSE (Ind-AS), consolidated. For information only, not investment advice.

alphave

GUFICBIO₹423.75

Gufic Biosciences Limited

· Pharma & Health

Annual Quarterly₹ CrorePeersRPGLIFE UNICHEMLAB GUJTHEM ORCHPHARMA SMSPHARMA INDSWFTLAB FDC IOLCPMcap ₹4,249 Cr

View

In ₹ Crore except Per Share 12 Months Ending	FY23 31/03/2023	FY24 31/03/2024	FY25 31/03/2025	FY26 31/03/2026	Last 12M 30/06/2026
Revenue from Operations	—	806.7	819.8	944.0	981.1
Other Income	—	2.2	3.6	2.7	2.2
Total Income	—	808.8	823.4	946.7	983.3
Expenses
+ Cost of Materials Consumed	—	341.3	344.2	425.3	443.0
+ Purchases of Stock-in-Trade	—	58.1	55.4	64.7	64.5
+ Changes in Inventories	—	-9.5	-24.9	-68.9	-72.0
+ Employee Benefit Expense	—	109.6	127.1	151.7	157.5
+ Finance Costs	—	15.4	23.1	36.6	36.7
+ Depreciation & Amortisation	—	17.0	21.1	30.8	30.8
+ Other Expenses	—	161.3	183.4	219.8	223.6
Total Expenses	—	693.2	729.3	860.1	884.0
EBITDA	—	145.9	134.7	151.3	164.6
EBIT	—	128.9	113.6	120.5	133.8
Profit
PBT before Exceptional Items	—	115.7	94.1	86.5	99.3
Pretax Income	—	115.7	94.1	86.5	99.3
+ Current Tax	—	26.4	18.7	13.7	17.6
+ Deferred Tax	—	3.2	5.8	8.6	8.3
Tax Expense	—	29.5	24.5	22.3	25.9
Net Income	—	86.1	69.6	64.2	73.5
+ Net Income — Continuing Ops	—	86.1	69.6	64.2	73.5
+ Other Comprehensive Income	—	-0.4	-0.1	0.5	0.6
Total Comprehensive Income	—	85.7	69.5	64.7	74.0
Net Income to Common	—	—	69.6	64.2	—
Minority Interest	—	—	-0.0	-0.0	—
Per Share
Basic EPS	—	8.74	6.95	6.40	7.32
Diluted EPS	—	8.74	6.95	6.40	7.32
Other Comprehensive Income — detail
+ Other Comprehensive Income	—	—	-0.1	0.5	—
+ Items NOT to be Reclassified to P&L	—	-0.5	-0.2	0.7	—
+ Tax on Items NOT to be Reclassified	—	—	-0.0	0.2	—
+ Tax on Items NOT to be Reclassified — alt tag	—	-0.1	—	—	—
Comprehensive Income — Owners of Parent	—	—	69.6	64.2	—
Comprehensive Income — Non-controlling Interests	—	—	-0.0	-0.0	—
Per Share — as-filed variants
Basic EPS — Continuing Operations	—	8.74	6.95	6.40	7.32
Diluted EPS — Continuing Operations	—	8.74	6.95	6.40	7.32
Derived — Gross Profit (Revenue − Materials − Purchases − Δ Inventories)
Gross Profit	—	416.8	445.1	522.8	545.7
Gross Margin %	—	51.67	54.29	55.38	55.62
Adjusted (ex-Exceptional Items) — derived
Pretax Income (Adjusted, as filed)	—	115.7	94.1	86.5	99.3
Net Income Adj (tax-effected)	—	86.1	69.6	64.2	73.5
EPS Adj	—	8.74	6.95	6.40	7.32
Other Filed Concepts — mapped but not yet placed in the schedule
Face Value	—	1.00	1.00	1.00	1.00
Paid Up Equity Capital	—	10.0	10.0	10.0	10.0

As filed, sign as filed — read the label, not the sign. A line appears only when the company tagged that concept in at least one period shown, so depth follows the filer: pre-Ind-AS, insurance and NBFC blocks stay hidden unless they were actually reported. Alternate tags for the same idea (e.g. two spellings of a deferred-tax element) are kept as separate lines rather than merged, because merging them would be a guess. Ratios, per-share figures and counts render as raw numbers, not ₹ Crore. No consensus estimates → no Est columns. Click any row to chart it.

« ‹ › »Latest: FY26 · ConsolidatedFA Financial Analysis · alphave

Data & compliance. Descriptive financial information from official NSE/BSE filings — for information and education only, not investment advice, a recommendation, or a valuation. Standalone = parent entity; consolidated includes subsidiaries. Historical multiples pair each fiscal year's filed figures with that FY-end market close; the Current column uses the last close with the latest filed annuals. Figures are cross-verified via accounting identities and NSE×BSE agreement — XBRL cross-verified ✓ 95%.